Dermatology Advisor

DermatologyAdvisor.com serves as a valuable resource for dermatologists and healthcare professionals, delivering a wealth of practical information and tools to help them make informed decisions for their patients. The goal of Dermatology Advisor is to equip dermatologists and healthcare providers who treat skin and related conditions with up-to-date, relevant educational content that enhances their clinical practice and elevates patient care. The platform also offers practice management tools and continuing education programs, creating a comprehensive digital experience that tackles many challenges faced by dermatology professionals today.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#399260

United States

#185925

Health/Medicine

#1446

Traffic sources

Monthly visitors

Articles

Metabolic Score for Insulin Resistance Predicts Cardiovascular Risk in PsA

2 days ago | dermatologyadvisor.com | Hibah Khaja

Recent study results published in RMD Open suggest that the metabolic score for insulin resistance (METS-IR) is an effective predictor of cardiovascular (CV) events among patients with psoriatic arthritis (PsA). Using data from patients enrolled in the prospective CARdiovascular in RheuMAtology cohort, researchers in Spain evaluated whether METS-IR values could serve as a reliable predictor of CV risk among patients with PsA.
Fractional Erbium:YAG Laser With TXA Has No Consistent Benefit for Melasma

2 days ago | dermatologyadvisor.com | Lisa M Kuhns

Fractional erbium:YAG laser-assisted delivery of tranexamic acid (TXA) for melasma showed no consistent significant improvement compared with TXA monotherapy, with wide variability across studies, countries, and follow-up durations, according to study results published in Archives of Dermatological Research.
April 2025 Recap: Drug Pipeline Updates

3 days ago | dermatologyadvisor.com | Steve Duffy

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. DrugPharmacologic ClassProposed IndicationStatusCardiovascular DiseaseSemaglutide (Novo Nordisk)Glucagon-like peptide-1 receptor agonistTo improve walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.
Atopic Dermatitis Linked to Increased Risk of COVID-19 Infection

3 days ago | dermatologyadvisor.com | Ron Goldberg

The risk of COVID-19 infection is increased among patients with atopic dermatitis (AD) across sex and age groups, according to study findings published in The Journal of Dermatology. Investigators explored the relationship between AD and COVID-19 infection and any factors that might modify the infection risk among this patient population.
Biosimilar Selarsdi Now Interchangeable With Stelara

6 days ago | dermatologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Selarsdi™ (ustekinumab-aken) as interchangeable to the reference product Stelara® (ustekinumab).
Phototherapy With Topical Antioxidants Is Best Combination Therapy for Vitiligo

6 days ago | dermatologyadvisor.com | Jessica Nye

A network meta-analysis published in the Journal of Dermatological Treatment found that phototherapy combined with topical antioxidants, corticosteroids, or calcineurin inhibitors was associated with superior clinical outcomes for the treatment of vitiligo.
April 2025: Notable Drug Approvals

6 days ago | dermatologyadvisor.com | Steve Duffy

DrugPharmacologic ClassIndicationMore InformationAllergic DisordersDupixent (dupilumab)Interleukin-4 receptor alpha antagonistTreatment of patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.
Ceramide Skin Care Regimen Improves AD, Psoriasis, and Xerosis Symptoms

6 days ago | dermatologyadvisor.com | Lisa M Kuhns

Using a ceramide-containing skin care regimen significantly improves clinical symptoms and quality of life (QOL) in patients with atopic dermatitis (AD), psoriasis, and xerosis, and may reduce the need for corticosteroids and antihistamines, according to study results published in the Journal of Dermatological Treatment.
Higher Infection Rates With JAK Inhibitors vs Biologics in Atopic Dermatitis

1 week ago | dermatologyadvisor.com | Ron Goldberg

Treatment with Janus kinase inhibitors (JAKi) for moderate to severe atopic dermatitis (AD) was associated with higher infection rates than biologic therapies, especially for herpes infections and among those with a history of fungal or viral skin infections. These study findings were published in the Journal of the European Academy of Dermatology & Venereology.
Efficacy, Safety of SYSA1902 Is Similar to Reference Ustekinumab for Psoriasis

1 week ago | dermatologyadvisor.com | Lisa M Kuhns

The biosimilar SYSA1902 demonstrated clinical equivalence to reference ustekinumab in efficacy, safety, and immunogenicity for moderate to severe plaque psoriasis, according to study results published in the Journal of the American Academy of Dermatology. In a multicenter, randomized, double-blind, phase 3 trial conducted across 42 sites in China, researchers assigned 446 patients in a 1:1 ratio to receive either SYSA1902 45 mg (n=224) or ustekinumab 45 mg (n=222).